HiFiBiO Company

HiFiBiO is a biotherapeutics company that mobilizes the human immune system to combat disease. It commercializes proprietary single-cell technologies for applications in drug and biomarker discovery and development. It also aspires to benefit patients through open-innovation partnerships with industry and academia. HiFiBiO integrates deep-rooted biological expertise with its comprehensive single-cell profiling technologies to discover and accelerate a pipeline of antibody drugs to treat cancer and autoimmune disorders. The company was founded in 2013 and is headquartered in Paris, Ille-de-France.
Industry: Early Drug Development
Headquarters: Paris, Ile-de-France, France
Founded Date: 2013-01-01
Employees Number: 101-250
Funding Status: Late Stage Venture
Investors Number: 20
Total Funding: 179500000
Estimated Revenue: $1M to $10M
Last Funding Date: 2021-06-14
Last Funding Type: Series D

Visit Website
https://twitter.com/hifibio
Register and Claim Ownership